Glycemic Control in Patients with High HbA1c Levels

Introduction to GLP-1 Receptor Agonists and SGLT2 Inhibitors

The American Diabetes Association and European Association for the Study of Diabetes recommend considering GLP-1 receptor agonists or SGLT2 inhibitors for patients with HbA1c levels exceeding 9%, due to their efficacy in improving glycemic control, reducing cardiovascular risk, and promoting weight loss 1

GLP-1 receptor agonists have demonstrated efficacy in patients with HbA1c >9%, providing weight reduction benefits, lower risk of hypoglycemia, and cardiovascular benefits in patients with established disease 1
Examples of GLP-1 receptor agonists include semaglutide (weekly) or liraglutide (daily) 1
For patients with very high HbA1c levels (>11%), GLP-1 receptor agonists like semaglutide can be effective alternatives to early introduction of insulin 1

SGLT2 inhibitors are also effective for HbA1c >9%, offering weight reduction benefits, cardiovascular and renal protective effects 1
Examples of SGLT2 inhibitors include empagliflozin and dapagliflozin 1

Insulin intensification may be considered if symptoms of severe hyperglycemia are present, and may involve adding mealtime insulin if patient shows signs of significant insulin deficiency 1

Reassess HbA1c after 3 months of therapy to determine effectiveness and need for further adjustment, considering triple therapy or further insulin intensification based on patient response 1, 2
The American Diabetes Association and European Association for the Study of Diabetes recommend intensification of therapy in patients with HbA1c levels exceeding 9%, with additional benefits of weight reduction and reduced hypoglycemia risk, using SGLT2 inhibitors and GLP-1 receptor agonists like semaglutide 1
Be prepared to reduce glipizide dose if hypoglycemia occurs, as GLP-1 receptor agonists can potentiate the hypoglycemic effects of sulfonylureas, as recommended by the American Diabetes Association and European Association for the Study of Diabetes 1
Ensure the patient has no personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, as these are contraindications to semaglutide use 1